We report the case of a young woman with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, without tumor, who was successfully treated with rituximab. Because conventional immunotherapy, including corticosteroids, immunoglobulin (IVIg), and plasma exchange showed little improvement in our patient, we introduced another treatment using rituximab. A week after the first administration of rituximab, her symptoms improved gradually and significantly. This case provides in vivo evidence that rituximab is an effective agent for treating anti-NMDAR encephalitis, even in those cases where conventional immunotherapies have been ineffective. Rituximab should be regarded as a beneficial therapeutic agent for this disease.
Introduction
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune encephalitis that was first characterized by Dalmau and his colleagues in 2007 (1) . The disorder predominantly affects children and young adult women (2) . A previous report suggests that the encephalitis is associated with a tumor in almost 42% of the patients, but the precise pathological background and its relationship to the encephalitis remain elusive (2) .
Clinical features of the encephalitis are characterized by psychiatric symptoms, disturbance of consciousness, generalized seizures, abnormal involuntary movements, autonomic dysfunction, and central hypoventilation (2) (3) (4) . The diagnosis is based upon the clinical course of the condition and these neurological features. In addition, the demonstration of anti-NMDAR antibodies in the serum and cerebrospinal fluid (CSF) is essential for diagnosis.
The condition is treated by tumor removal (in those patients with a tumor), whereas first-line immunotherapy (corticosteroids plus intravenous immunoglobulin (IVIg) or plasma exchange) has been proposed in previous reports (2) .
When little or no response is seen after administration of these therapies, treatment with second-line immunotherapy (e.g., rituximab and/or cyclophosphamide) should be considered (2, 3, (5) (6) (7) (8) .
Here, we report the case of a young woman with anti-NMDAR encephalitis that was not associated with a tumor, who showed significant improvement in symptoms after administration of rituximab.
Figure 1. Electroencephalogram (EEG)
. Poor α organization with diffuse slowing of background activity was noted prior to the administration of immunotherapy, including rituximab (A). After rituximab was introduced, the abnormal activity on the EEG was markedly improved (B).
toms, such as crying out, perseveration, and stereotypic behaviors.
Hematological tests showed a white blood cell (WBC) count of 10,050 cells/μL (82% neutrophils, 11% lymphocytes). C-reactive protein (CRP) was 0.1 mg/dL. Creatine kinase level was 350 U/L. The CSF contained 14 leukocytes/μL (including 85% mononuclear cells) and 29 mg/dL of protein. The glucose level in the CSF was 76 mg/dL, while serum glucose level was 102 mg/dL. The IgG-index was 0.73, and IL-6 was slightly elevated (9.9 pg/mL). In addition, CSF culture proved to be negative for bacteria. Serological examination and polymerase chain reaction-based analysis of CSF for viruses, including herpes simplex virus, were not suggestive of any viral infection. Brain magnetic resonance imaging (MRI) demonstrated no remarkable abnormalities, even after enhancement with gadolinium chelate. Electroencephalogram (EEG) showed diffuse slow waves (Fig. 1) . Epileptogenic discharges were not detected. Whole body investigation by chest-abdominal computed tomography and MRI of the pelvis revealed no indication of a tumor lesion.
Because she manifested repetitive generalized convulsions and hyperventilation attacks several times a day, intravenous administration of acyclovir and phenytoin was initiated. Five days after admission (day 5), apnea and hyperventilation became apparent, followed by an autonomic instability characterized by intermittent bradycardia and hypersalivation. Two days later, she developed disturbance of consciousness, and artificial ventilation was required. She was treated with carbamazepine and continued intravenous administration of midazolam; however, these treatments had little effect on controlling the attacks. Therefore, subsequent intravenous infusion of vecuronium bromide was implemented. On day 9, orofacial dyskinesia became evident. Although treatment with methylprednisolone (1,000 mg/day for 3 days, 2 cycles), IVIg (0.4 g/kg -1 /day -1 for 5 days) and plasma exchange (7 times) was introduced from day 7 to day 74, her symptoms did not improve. The clinical profile of her symptoms was suggestive of anti-NMDAR encephalitis. We started weekly rituximab (adhering to the administration protocol of rituximab approved by the Ethics Committee of Saitama Red Cross Hospital), for a total of 4 doses (a monoclonal anti-CD20 antibody, 375 mg/m -2 /week -1 ), on day 100. A week after the first administration of rituximab, her clinical symptoms, including fever, consciousness disturbance, involuntary movement, and autonomic instability, markedly improved (Fig. 2) . In parallel with these symptomatic improvements, the findings on EEG were normalized (Fig. 1) . Antibody to the NMDAR was detected both in her serum and CSF, which were collected before immunotherapy, including corticosteroids, IVIg, and plasma exchange had been initiated. These samples were collected on day 7 and sent to Dr. Dalmau's laboratory (Department of Neurology, University of Pennsylvania), where the presence of anti-NMDAR antibodies was revealed on day 113. Therefore, she was diagnosed with anti-NMDAR encephalitis. Improvements of respiratory failure were relatively slow, and she was started on azathioprine (50 mg/day) treatment from day 160. On day 207, she was successfully weaned off artificial ventilation. Although disorientation and mild involuntary movement persisted, she was able to not only eat and walk unassisted, but also to draw a simple picture and write characters. On day 227, she was transferred to another hospital for rehabilitation.
Although brain MRI did not reveal any abnormal intensities in this case, normal mouse brain parenchyma showed focal immunoreactions to serum samples from this patient that were collected on day 57 (after administration of firstline immunotherapy and before administration of rituximab) (Fig. 3) . The cytoplasm of Purkinje cells and the dendritic layer were markedly immunopositive to the patient's serum (Fig. 3) .
Discussion
In this study, we describe the reduction in symptoms and EEG abnormalities in a young woman with anti-NMDAR encephalitis without an associated tumor by administration of rituximab. A previous report suggests that a tumor, mostly ovarian teratoma (2), could be identified in 42% of patients with anti-NMDAR encephalitis; however, no causative tumor lesions could be identified in the remainder of such patients. In patients without a tumor, first-line immunotherapy, using corticosteroids, IVIg, plasma exchange may not be effective, thus second-line immunotherapy (e.g., rituximab and/or cyclophosphamide) is usually needed (2, 3, (5) (6) (7) (8) (9) .
The immunopathogenesis of this encephalitis is possibly related to antibody immune-responses of B cell and antibody-secreting cells (e.g., plasma cells), which are derived from activated B cells (10) (11) (12) . In the present case, normal mouse brain showed immunoreactions to serum samples from this patient, which had been collected after administration of first-line immunotherapy, and before the administration of rituximab. This immunoreaction was similar to that to commercially available anti-glutamate receptor (GluR) δ2-antibody. GluRδ2 shares a partial epitope with NMDAR, which is a well-known protein present on cerebellar Purkinje cells. Thus, our experimental results supported the immunological evidence that this patient's serum sample includes an antibody with affinity to NMDAR. Rituximab causes a decrease in B cells and prevents maturation of these cells into antibody-secreting cells (10) ; it also suppresses B cell function more selectively and continuously than first-line immunotherapy (13) (14) (15) (16) (17) (18) (19) . In addition, this agent causes a form of immune system resetting due to the depletion of memory B cells (19, 20) . Depletion of B cells inhibits its antigen-presenting role and cytokine secretion function, which prevents stimulating T cells (20, 21) . Therefore, rituximab may be effective for treatment of anti-NMDAR encephalitis that is resistant to first-line immunotherapy.
It is well known that the typical adverse effects of rituximab are infusion-related reactions, leukocytopenia, hypogammaglobulinemia, and infection, whereas progressive multifocal leukoencephalopathy (PML) and reactivation of hepatitis B virus are rare, but important, complications of rituximab (22) . Although infusion-related reactions, such as fever, were seen in this case, these resolved immediately, and there were no serious adverse effects during follow-up.
Cyclophosphamide is also recommended as second-line immunotherapy for anti-NMDAR encephalitis (2, 3, 8) ; however, dose-dependent gonadal toxicity and infertility might be serious disadvantages for young patients, in addition to the other negative side effects, including malignancy, hemorrhagic cystitis, myelosuppression, alopecia, and infection (23) (24) (25) (26) . Thus, considering the B cell-selective pharmacological effects and the limited side effects of rituximab, this therapy might be particularly useful in young anti-NMDAR encephalitis patients without tumor lesions (2, 5, 7, 13, 14, 20, (27) (28) (29) (30) .
More detailed clinical analysis is necessary to elucidate the etiology of anti-NMDAR encephalitis. Awareness of the probable effectiveness of rituximab for this type of encephalitis may both enhance our understanding of the disease and facilitate the appropriate treatment of patients with anti-NMDAR encephalitis.
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